Previous 10 | Next 10 |
CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the “Company”, “Cyclerion Therapeutics”, “Cyclerion”) (Nasdaq: CYCN) announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ...
2023-05-12 02:59:46 ET Cyclerion Therapeutics ( NASDAQ: CYCN ) enter agreement to sell two of its sGC stimulator assets in exchange for cash and equity ownership to a new private company. Investors will park $81M to develop zagociguat to treat MELAS* and other diseases ass...
Certain Cyclerion shareholders and new investors have agreed to invest $81M to launch a new company targeting diseases of mitochondrial dysfunction Cyclerion to receive $8M in cash and 10% equity in the new company in exchange for its zagociguat and CY3018 assets Definitive agre...
Definitive agreement reached with new company (“NewCo”) established by certain Cyclerion shareholders and new investors Cyclerion to receive $8M in cash and 10% equity in NewCo in exchange for its zagociguat and CY3018 assets Definitive agreement signing triggers p...
CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company, acting solely by all of its independent and disinterested members (the “Independent Board”), has reviewed a non-binding propos...
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designatio...
CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates including advances in its zagociguat (formerly CY6463) mitochondrial disease program. The Company previously reported clinical data in adult patients with MELAS...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com It’s time to start the week with a breakdown of the biggest pre-market stock movers to keep a watch on Monday! Moving stocks this morning are clinical trial results, a bankru...
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company acting solely by all of its independent and disinterested members (the “Independent Board”) has reviewed the non-binding a...
Cyclerion Therapeutics ( NASDAQ: CYCN ) on Thursday said it would reduce its workforce by about 45% as part of a strategic prioritization to focus its resources on the development of its therapy CY6463 for the treatment of mitochondrial diseases. Shares of the micro-ca...
News, Short Squeeze, Breakout and More Instantly...
Cyclerion Therapeutics Inc. Company Name:
CYCN Stock Symbol:
NYSE Market:
Cyclerion Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 1.8% to $131.88 on volume of 307,014,213 shares SRIVARU Holding Limited (SVMH) rose 49.2% to $0.2275 on volume of 274,465,266 shares Nauticus Robotics Inc. (KITT) rose 19.6% to $0.192 on volume of 161,46...
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) is one of today's top gainers. The company's shares have moved 37.28% on the day to $2.81. Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serio...